Carmustine

Generic Name
Carmustine
Brand Names
Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
Drug Type
Small Molecule
Chemical Formula
C5H9Cl2N3O2
CAS Number
154-93-8
Unique Ingredient Identifier
U68WG3173Y
Background

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...

Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Associated Conditions
Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

First Posted Date
2003-01-27
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
87
Registration Number
NCT00005987
Locations
🇺🇸

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2016-02-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
170
Registration Number
NCT00002766
Locations
🇺🇸

Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States

🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 4 locations

Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma

Phase 3
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2009-02-09
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
427
Registration Number
NCT00052923

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
8
Registration Number
NCT00003567
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme

First Posted Date
2003-01-27
Last Posted Date
2020-10-22
Lead Sponsor
Radiation Therapy Oncology Group
Target Recruit Count
80
Registration Number
NCT00006386
Locations
🇺🇸

Robert and Beverly Lewis Family Cancer Care Center, Pomona, California, United States

🇺🇸

O'Connor Hospital, San Jose, California, United States

🇺🇸

CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States

and more 233 locations

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2003-01-27
Last Posted Date
2019-11-04
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
22
Registration Number
NCT00003727
Locations
🇺🇸

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma

First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
17
Registration Number
NCT00004072
Locations
🇺🇸

MetroHealth Medical Center, Cleveland, Ohio, United States

🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2010-06-10
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
37
Registration Number
NCT00028665
Locations
🇺🇸

Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

Phase 3
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2013-09-17
Lead Sponsor
German Hodgkin's Lymphoma Study Group
Target Recruit Count
220
Registration Number
NCT00025636
Locations
🇧🇪

Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium

🇩🇪

Universitaetsklinikum Essen, Essen, Germany

🇩🇪

Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet, Greifswald, Germany

and more 41 locations

Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-01-27
Last Posted Date
2013-06-20
Lead Sponsor
Duke University
Target Recruit Count
68
Registration Number
NCT00003467
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy